Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $230.00 → $260.00 | Neutral → Overweight | Piper Sandler |
| 2/6/2024 | $253.00 | Overweight | KeyBanc Capital Markets |
| 5/30/2023 | $206.00 | Equal-Weight | Morgan Stanley |
| 4/14/2023 | $215.00 → $197.00 | Overweight → Neutral | Piper Sandler |
| 9/23/2022 | Buy → Hold | Needham | |
| 7/14/2022 | $240.00 | Overweight | Piper Sandler |
| 4/7/2022 | $275.00 | Outperform | Wolfe Research |
| 2/14/2022 | $250.00 → $270.00 | Market Outperform | JMP Securities |
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re
DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se
DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re
DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se
DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,
Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously
KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00
Morgan Stanley initiated coverage of Steris with a rating of Equal-Weight and set a new price target of $206.00
DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal
David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W
144 - STERIS plc (0001757898) (Subject)
8-K - STERIS plc (0001757898) (Filer)
8-K - STERIS plc (0001757898) (Filer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)